`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`Celltrion, Inc.
`Petitioner,
`
`v.
`
`Genentech, Inc.
`Patent Owner
`
`Patent No. 6,407,213
`
`
`
`
`
`Inter Partes Review No. IPR2017-01374
`
`
`PETITIONER’S SIXTH UPDATED MANDATORY NOTICES
`
`
`
`
`
`
`
`Celltrion, Inc. hereby updates its Mandatory Notices pursuant to 37 C.F.R. §
`
`42.8 to update related matters.
`
`Patent No. 6,407,213 (“the ’213 patent”) is related to the following patents:
`
`U.S. Pat. Nos. 6,639,055, 6,800,738, and 6,719,971 (all expired for maintenance fee
`
`non-payment), and U.S. Pat. No. 8,075,890.
`
`Petitioner additionally challenged claims of the ’213 patent in IPR2017-
`
`01373, which was instituted. Pfizer Inc. challenged the ’213 patent in IPR2017-
`
`01488 and IPR2017-01489, which were both instituted. Boehringer Ingelheim
`
`Pharmaceuticals, Inc. challenged the ’213 patent in IPR2017-02031 and
`
`IPR2017-02032, which were both instituted. Samsung Bioepis Co., Ltd. challenged
`
`the ’213 patent in IPR2017-02139 and IPR2017-02140. These proceedings were
`
`instituted and joined with IPR2017-01488 and IPR2017-01489, respectively.
`
`Mylan Pharmaceuticals Inc. challenged the ’213 patent in IPR2016-01693 and
`
`IPR2016-01694, which were both terminated.
`
`The ’213 patent is at issue in the following litigations: Amgen Inc. v.
`
`Genentech, Inc. et al, No. 17-cv-7349 (C.D. Cal.) (now dismissed); Genentech,
`
`Inc. et al v. Amgen Inc., No. 17-cv-1407 (D. Del.); Genentech, Inc. et al v. Amgen
`
`Inc., No. 17-cv-1471 (D. Del.); Genentech, Inc. v. Pfizer, Inc., No. 17-cv-1672
`
`(D. Del.); Celltrion, Inc. v. Genentech, Inc., No. 18-cv-274 (N.D. Cal.) appeal
`
`docketed, No. 18-2160 (Fed. Cir. July 16, 2018); Genentech, Inc. v. Celltrion,
`
`
`
`2
`
`
`
`Inc., No. 18-cv-095 (D. Del.); Genentech, Inc. et al. v. Amgen Inc., No. 18-cv-
`
`924 (D. Del.); Genentech, Inc. et al. v. Celltrion, Inc. et al., No. 18-cv-1025 (D.
`
`Del.); and Genentech, Inc. et al. v. Samsung Bioepis Co., Ltd., No. 18-cv-1363
`
`(D. Del.).
`
`Dated: October 1, 2018
`
`By: /Cynthia Lambert Hardman/
`Cynthia Lambert Hardman (Reg. No. 53,179)
`Elizabeth J. Holland(Reg. No. 47,657)
`Robert V. Cerwinski (admitted pro hac vice)
`Linnea P. Cipriano (Reg. No. 67,729)
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`(212) 813-8800 (telephone)
`(212) 355-3333 (facsimile)
`
`
`
`Sarah J. Fischer (Reg. No. 74,104)
`GOODWIN PROCTER LLP
`100 Northern Avenue
`Boston, MA, 02210
`(617) 570-3908 (telephone)
`(617) 801-8991 (facsimile)
`
`Counsel for Petitioner
`
`
`
`3
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 1st day of October,
`
`2018, I caused a copy of this PETITIONER’S SIXTH UPDATED MANDATORY
`
`NOTICES to be served by email on the lead and back up counsel for Patent Owners
`
`at:
`
`
`
`
`
`
`
`David Cavanaugh (David.Cavanaugh@wilmerhale.com)
`
`Lauren V. Blakely (lauren.blakely@wilmerhale.com)
`
`Robert Gunther (Robert.Gunther@wilmerhale.com)
`
`Adam Brausa (abrausa@durietangri.com)
`
`Daralyn Durie (ddurie@durietangri.com)
`
`Andrew Danford (Andrew.Danford@wilmerhale.com)
`
`Lisa Pirozzolo (Lisa.Pirozzolo@wilmerhale.com)
`
`Kevin Prussia (Kevin.Prussia@wilmerhale.com)
`
`/Cynthia Lambert Hardman/
`
`Cynthia Lambert Hardman (Reg. No.
`53,179)
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`(212) 813-8800 (telephone)
`(212) 355-3333 (facsimile)
`
`
`
`